Evaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms

doi:10.5306/wjco.v17.i1.111426

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

This Article

(44)

(41)

(0)

(9)

(466)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Jan 24, 2026; 17(1): 111426
Published online Jan 24, 2026. doi: 10.5306/wjco.v17.i1.111426

Table 2 Treatment protocols among patients

Initial treatment type	Frequency	Percent (%)	Initial chemotherapy type	Frequency	Percent (%)
CTH	62	87.3	CyBorD	37	52.1
CTH and RTH	8	11.3	VAD	29	40.8
RTH	1	1.4	Daratumumab	4	5.6

CTH: Chemotherapy; RTH: Radiotherapy; CyBorD: Cyclophosphamide, bortezomib, and dexamethasone; VAD: Vincristine, adriamycin (doxorubicin), and dexamethasone.

Full Size Table

Citation: Ebrahim NAA, Elfandy H, Arafat AMA, Darwish AD, Eltohamy MI. Evaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms. World J Clin Oncol 2026; 17(1): 111426
URL: https://www.wjgnet.com/2218-4333/full/v17/i1/111426.htm
DOI: https://dx.doi.org/10.5306/wjco.v17.i1.111426

Ebrahim NAA, Elfandy H, Arafat AMA, Darwish AD, Eltohamy MI. Evaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms. World J Clin Oncol 2026; 17(1): 111426 [PMID: 41608334 DOI: 10.5306/wjco.v17.i1.111426]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.